Weight-Loss Bali supplies the GLP-1 class research peptides most studied in metabolic research (Retatrutide, Tirzepatide and Semaglutide), delivered across Bali for research use.
Replies in minutes. No prepayment, you pay on confirmation.
Discreet delivery across Bali, usually within hours.
Compounds sourced for purity and consistency.
Plain, unmarked packaging to your villa or clinic.
Kept cool in transit to protect the compound.
Research-use pricing, current June 2026. Confirm the latest on WhatsApp.
Dual GIP/GLP-1 receptor agonist, studied in metabolic research.
Order on WhatsApp
Triple receptor agonist; verifiable third-party COA.
See COA →Order on WhatsApp
GLP-1 receptor agonist, among the most-studied metabolic peptides.
Order on WhatsAppFree same-day delivery included. No prepayment to enquire: we confirm stock, price and delivery first. Pay by bank transfer, card payment link, crypto, or cash on delivery.
Just researching? Message "PRICES" and we send the full list →
Real Google reviews of the Peptide+ service, rated 5.0 from 78+ reviews.
My favourite peptide company in Bali. Best pricing and fast delivery. I highly recommend buying your peptides here.
Best peptides in Bali. Good consultation and the delivery was quick. All around good customer service.
Great service, very happy. Will buy again. Also added extra bits with the order that I'm very grateful for.
Good communication and fast delivery. Very good company.
Best peptide shop in Bali. Great service. Recommended.
GLP-1 and dual/triple receptor-agonist peptides are among the most-studied compounds in metabolic research.
Supplied strictly for laboratory and research purposes. Not for human or veterinary use.
These compounds are studied across the key metabolic receptor pathways.
Studied for its role in appetite and metabolic-signalling research.
Investigated in nutrient-processing and metabolic research.
Studied in energy-metabolism research, the third pathway of triple agonists.
Retatrutide, Tirzepatide and Semaglutide, all in one place.
Same-day, discreet, cold-chain delivery across Bali.
WhatsApp guidance on reconstitution and storage.
Tell us the compound and your area.
No prepayment. Pay on confirmation by bank transfer, card link, crypto, or cash on delivery.
Discreet, cold-chain delivery to your door, usually within hours.
| Class | GLP-1 / dual / triple receptor agonists |
| Compounds | Retatrutide, Tirzepatide, Semaglutide |
| Format | Lyophilised vials / pre-measured pens |
| Storage | Cool, dark; refrigerate after reconstitution |
| Reconstitution | Bacteriostatic water |
| Delivery | Same-day across Bali; nationwide shipping |
| Use | Laboratory & research only |
The weight-loss peptides in Bali sold under this range belong to the GLP-1 class of receptor agonists, a group of hormone mimicking molecules studied for their role in appetite and metabolic signalling. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist, acting on both the GIP and GLP-1 receptors. Retatrutide goes a step further as a triple agonist, adding glucagon receptor activity on top of the GIP and GLP-1 pathways already covered by the other two.
The trial evidence for each compound comes from large randomised studies conducted in adults with obesity. Semaglutide's STEP 1 trial, published by Wilding and colleagues in the New England Journal of Medicine in 2021, tested once weekly semaglutide against placebo in adults with overweight or obesity. Tirzepatide's SURMOUNT-1 trial, published by Jastreboff and colleagues in the same journal in 2022, tested tirzepatide at several doses in a broadly similar population. Retatrutide's phase 2 trial, also led by Jastreboff and published in the New England Journal of Medicine in 2023, tested the triple agonist across a dose range in adults with obesity.
Semaglutide and tirzepatide are now approved prescription medicines in several countries for weight management, following the trial programs described above. Retatrutide is the newest of the three. Its phase 2 results were published in 2023 and its phase 3 programme followed, so it has a smaller and more recent evidence base than the other two and none of their approval history.
As this page notes, Retatrutide carries a verifiable third party Janoshik certificate of analysis that can be checked directly online. Tirzepatide and Semaglutide are not shown with that same certificate on this page.
These compounds are supplied here as lyophilised vials or, where available, pre measured pens, as described elsewhere on this page. Vials need reconstituting with bacteriostatic water before use, which allows flexible measuring for a research protocol, while pens arrive pre measured and ready for immediate use.
All three compounds should be kept cool and out of light before use. Once reconstituted, they need refrigeration and should be used within the compound's usual stability window rather than left out between research sessions. As this page notes, delivery is handled cold chain, and that window between delivery and refrigeration is the point where a vial or pen is most likely to be left at room temperature by mistake.
A dual agonist, like tirzepatide, activates two hormone receptor pathways at once, GIP and GLP-1. A triple agonist, like retatrutide, adds a third pathway, the glucagon receptor. Researchers study whether combining additional pathways changes the metabolic effects seen compared with a single pathway compound alone.
No. Semaglutide and tirzepatide have completed phase 3 trials and are approved prescription medicines in several countries. Retatrutide is the newest: its phase 2 results came out in 2023 and its phase 3 programme followed, so its evidence base is smaller and more recent than the other two.
STEP 1, published in 2021, tested once weekly semaglutide against placebo in adults with overweight or obesity over roughly 68 weeks, alongside a lifestyle intervention that both groups received, and reported on weight change and safety outcomes across that full trial population.
SURMOUNT-1, published in 2022, tested tirzepatide at multiple doses against placebo in adults with obesity or overweight, again alongside a lifestyle intervention given to every participant, and stands as the main phase 3 evidence behind tirzepatide's approval as a prescription medicine.
Because it is the only compound in this range that currently has one. Retatrutide carries a verifiable Janoshik certificate of analysis linked directly from this page for anyone to check. Tirzepatide and Semaglutide are not shown with a certificate here, and we do not claim testing we cannot show you.
They are metabolic research compounds, mainly GLP-1 and dual/triple receptor agonists such as Retatrutide, Tirzepatide and Semaglutide, studied for their effects on metabolic pathways. Supplied for research use only.
Retatrutide, Tirzepatide and Semaglutide, as vials and, where available, pre-measured research pens.
Select compounds, such as Retatrutide, have a verifiable Janoshik Certificate of Analysis you can open yourself. Ask us which batch is current.
Message us on WhatsApp with the compound and your Bali location. We confirm stock, price and delivery, with payment on confirmation.
Same-day across most of Bali. Nationwide shipping from Bali is also available.
No. All compounds are supplied strictly for laboratory and research purposes, not for human or veterinary use, and we make no medical or weight-loss claims.
Keep lyophilised compounds cool and out of light. After reconstitution, refrigerate and use within the typical window.
With bacteriostatic water. We can guide you through the process on WhatsApp.
Canggu · Berawa · Pererenan · Seminyak · Petitenget · Kerobokan · Legian · Kuta · Denpasar · Sanur · Ubud · Uluwatu · Pecatu · Bingin · Jimbaran · Nusa Dua · Tanjung Benoa · Tabanan · Sukawati · Gianyar
Nationwide shipping from Bali also available.
Message Weight-Loss Bali on WhatsApp for GLP-1 class metabolic research peptides, delivered across Bali for research use.
Order on WhatsAppReplies in minutes. No prepayment, you pay on confirmation.
